Evropská unie - čeština - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - karcinom, plicní jiná než malobuněčná - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

Evropská unie - čeština - EMA (European Medicines Agency)

stemline therapeutics b.v. - elacestrant - neoplasmy prsů - endokrinní terapie - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

vipharm s.a., ożarów mazowiecki array - 17375 erlotinib-hydrochlorid - potahovaná tableta - 100mg - erlotinib

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

vipharm s.a., ożarów mazowiecki array - 17375 erlotinib-hydrochlorid - potahovaná tableta - 150mg - erlotinib